Skip to main content
MedPathMedPath Home
Clinical Trials/IRCT20200928048862N1
IRCT20200928048862N1
Completed
Phase 1

The effect of duloxetine in quality of life and symptoms of patients with irritable bowel syndrome (IBS)

Iran University of Medical Sciences0 sites60 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
Iran University of Medical Sciences
Enrollment
60
Status
Completed
Last Updated
5 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
5 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • •Patients with irritable bowel syndrome (IBS)
  • •Mild to moderate score (score less than 11\) in the Anxiety and Depression Questionnaire.

Exclusion Criteria

  • •Psychotic patients, bipolar disorder, obsessive\-compulsive disorder, substance use in the last 6 months, dementia, suicidal idea
  • •Taking psychotropic drugs in the last 2 weeks
  • •Pregnancy and lactation
  • •age of under 18 years old and over 65 years old
  • •digestive bleeding
  • •Persistent vomiting
  • •Persistent abdominal pain
  • •Unexplained weight loss
  • •Crohn's, celiac disease, colon cancer, seizures, hypertension, angle\-closure glaucoma,

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not yet recruiting
Phase 2
Duloxetine and the symptoms and quality of life of patients with irritable bowel syndrome
IRCT20190404043159N1Esfahan University of Medical Sciences40
Not yet recruiting
Phase 2
the effect of duloxetine on theanxiety and depression of patients with diabetic neuropathyCondition 1: Effect of Duloxetine on the Mental State of Patients (Anxiety) with Diabetic Neuropathy. Condition 2: Effect of Duloxetine on the Mental State of Patients (Depression) with Diabetic Neuropathy.Diabetes mellitus due to underlying condition with diabetic autonomic (poly)neuropathyE08.43
IRCT20210725051977N2Islamic Azad University30
Recruiting
Not Applicable
Investigation on the effects of duloxetine on depressive symptoms and sleep disturbancesmajor depression
JPRN-UMIN000006386Department of Neuropsychiatry, Kagawa University School of Medicine30
Completed
Phase 4
Functional Change and Efficacy of Duloxetine in Patients With Co-Morbid Depression & Soft Tissue Discomfort SyndromeMajor Depressive DisorderSoft Tissue Discomfort SyndromePain
NCT01035073University of Pennsylvania22
Recruiting
Phase 2
Investigating the effect of Duloxetine in improving complications caused by vincristine treatment in children with cancer
IRCT20230827059268N1Shahid Beheshti University of Medical Sciences56